Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says

MT Newswires Live06-29

Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin updates risk eroding newly ascribed orexin-related value, BofA Securities said in a research note Monday.

ALKS largely trades on data points informing the commercial opportunity for its phase 2 and phase 3 pipeline asset orexin in hypersomnolent disorders, the brokerage said.

The firm said possible negative catalysts include Alkermes' phase 2 Vibrance-3 data in idiopathic hypersomnia, reading out late 2026 or early 2027.

BofA sees idiopathic hypersomnia as a risky segment in the broader hypersomnia market, as competition from Takeda Pharmaceutical's (TAK) phase 2 data for TAK-360 in narcolepsy type 2 and idiopathic hypersomnia could reinforce the narrative that the market is crowded. Key opinion leaders have also flagged lower unmet need for another wake promoter, and BofA sees profit and loss risk as well, according to the note.

BofA downgraded Alkermes to underperform from neutral with a price target of $38.

Price: 52.85, Change: -2.23, Percent Change: -4.05

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647080113?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647080113","market":"sh","top_or_hot":-1,"title":"Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says","media":"MT Newswires Live","content":"<html><body><p> Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin updates risk eroding newly ascribed orexin-related value, BofA Securities said in a research note Monday.</p><p>ALKS largely trades on data points informing the commercial opportunity for its phase 2 and phase 3 pipeline asset orexin in hypersomnolent disorders, the brokerage said.</p><p>The firm said possible negative catalysts include Alkermes' phase 2 Vibrance-3 data in idiopathic hypersomnia, reading out late 2026 or early 2027.</p><p>BofA sees idiopathic hypersomnia as a risky segment in the broader hypersomnia market, as competition from Takeda Pharmaceutical's (TAK) phase 2 data for TAK-360 in narcolepsy type 2 and idiopathic hypersomnia could reinforce the narrative that the market is crowded. Key opinion leaders have also flagged lower unmet need for another wake promoter, and BofA sees profit and loss risk as well, according to the note.</p><p>BofA downgraded Alkermes to underperform from neutral with a price target of $38.</p><p>Price: 52.85, Change: -2.23, Percent Change: -4.05</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-29 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin updates risk eroding newly ascribed orexin-related value, BofA Securities said in a research note Monday.</p><p>ALKS largely trades on data points informing the commercial opportunity for its phase 2 and phase 3 pipeline asset orexin in hypersomnolent disorders, the brokerage said.</p><p>The firm said possible negative catalysts include Alkermes' phase 2 Vibrance-3 data in idiopathic hypersomnia, reading out late 2026 or early 2027.</p><p>BofA sees idiopathic hypersomnia as a risky segment in the broader hypersomnia market, as competition from Takeda Pharmaceutical's (TAK) phase 2 data for TAK-360 in narcolepsy type 2 and idiopathic hypersomnia could reinforce the narrative that the market is crowded. Key opinion leaders have also flagged lower unmet need for another wake promoter, and BofA sees profit and loss risk as well, according to the note.</p><p>BofA downgraded Alkermes to underperform from neutral with a price target of $38.</p><p>Price: 52.85, Change: -2.23, Percent Change: -4.05</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647080113","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647080113","pubTimestamp":1782746061,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alkermes  stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin updates risk eroding newly ascribed orexin-related value, BofA Securities said in a research note Monday.ALKS largely trades on data points informing the commercial opportunity for its phase 2 and phase 3 pipeline asset orexin in hypersomnolent disorders, the brokerage said.The firm said possible negative catalysts include Alkermes' phase 2 Vibrance-3 data in idiopathic hypersomnia, reading out late 2026 or early 2027.BofA sees idiopathic hypersomnia as a risky segment in the broader hypersomnia market, as competition from Takeda Pharmaceutical's  phase 2 data for TAK-360 in narcolepsy type 2 and idiopathic hypersomnia could reinforce the narrative that the market is crowded. Key opinion leaders have also flagged lower unmet need for another wake promoter, and BofA sees profit and loss risk as well, according to the note.BofA downgraded Alkermes to underperform from neutral with a price target","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TAK":"武田制药","BK4139":"生物科技","ALKS":"阿尔凯默斯"},"translate_title":"美国银行表示，Alkermes面临即将发布的更新带来的食欲素相关价值风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALKS":1,"TAK":1},"content_text":"Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin updates risk eroding newly ascribed orexin-related value, BofA Securities said in a research note Monday.ALKS largely trades on data points informing the commercial opportunity for its phase 2 and phase 3 pipeline asset orexin in hypersomnolent disorders, the brokerage said.The firm said possible negative catalysts include Alkermes' phase 2 Vibrance-3 data in idiopathic hypersomnia, reading out late 2026 or early 2027.BofA sees idiopathic hypersomnia as a risky segment in the broader hypersomnia market, as competition from Takeda Pharmaceutical's (TAK) phase 2 data for TAK-360 in narcolepsy type 2 and idiopathic hypersomnia could reinforce the narrative that the market is crowded. Key opinion leaders have also flagged lower unmet need for another wake promoter, and BofA sees profit and loss risk as well, according to the note.BofA downgraded Alkermes to underperform from neutral with a price target of $38.Price: 52.85, Change: -2.23, Percent Change: -4.05","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647080113","isCrawlerRequest":true}